CBD for Arthritis: Does It Help Joint Pain? (November 2026)

Reviewed by: Bryan Doner, MD, & Cannabidiol Life’s Medical Review Team

INTRODUCTION:

In the Arthritis Foundation’s 2019 survey of more than 2,600 people with arthritis, 29% said they currently used CBD for their arthritis symptoms. See what human trials have found so far.
Wooden knitting needles resting on an undyed wool skein in a woven basket on a light oak table

Table of Contents

Data as of October 23, 2026; trial data updated November 13, 2026

Research on CBD for arthritis is mixed and low-certainty. CBD, or cannabidiol, is a non-intoxicating compound from hemp. The clearest positive result is for CBD on the skin: in a placebo-controlled cream trial in people with thumb arthritis, pain and function scores improved; two knee trials of CBD on the skin did not meet their main goal, though one favored its lower dose in a secondary analysis. In a 36-person placebo-controlled pilot of oral CBD around knee replacement, a post hoc test found lower opioid use with 400 mg than with placebo, though the planned test found no significant difference (Sideris 2026). In three placebo-controlled trials (Vela, Pramhas, Mojoli), oral CBD did no better than placebo for pain.

The FDA has not approved CBD for arthritis. The FDA has approved only one drug that contains CBD: Epidiolex, a prescription medicine for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in people 1 year of age and older.

On this page: Key takeaways · What CBD is · Research · Trial table · By type and joint · CBD cream · By the numbers · Doses and forms in studies · Standard care · Safety · Product quality · Legal status · FAQ · How we researched this · All trials · Safety and legal information · Sources

Key takeaways

  • Of 7 placebo-controlled trials of CBD without THC with results in a journal or conference abstract (721 people), a thumb-cream trial met its main goal; a knee-gel trial and an oral knee-replacement pilot missed their main measures, though a secondary analysis (gel) and a post hoc test (pilot) favored the lower dose; the other 4, including all 3 oral trials in arthritis itself, found no difference from placebo (Evidence Tracker; Heineman 2022; Sideris 2026).
  • 2026 reviews: a scoping review called topicals the most encouraging form, though not yet ready for routine clinical use; a chronic-pain review in which 64% of people had nerve pain found low-THC, CBD-dominant products may not improve pain (25 trials), and 4 pooled osteoarthritis trials showed no significant benefit (meta-analysis).
  • Safety: a 2026 review found CBD alone may not have increased harms in short trials. In a 2025 trial, 5.6% of healthy adults taking a daily CBD dose the authors said is higher than consumers commonly use had liver enzymes above 3 times the upper limit of normal within 4 weeks, vs 0% on placebo (Florian 2025).
  • 32 registered studies, 12 completed, as of October 23, 2026 (Evidence Tracker).

What is CBD, and how does it compare with THC, CBG and hemp seed oil?

CBD (cannabidiol) is a non-intoxicating cannabinoid from hemp (Cannabis sativa); THC is the intoxicating one (NCCIH). Some CBD products contain THC, even when the label says they don’t (lab tests); see full-spectrum vs broad-spectrum vs pure CBD. We found no CBG-only arthritis trial.

Is hemp oil the same as CBD oil?

No. Hemp seed oil is made from hemp seeds, and the FDA says hemp seeds do not naturally contain CBD or THC; seed foods carry only trace amounts picked up during processing (FDA). A 2025 knee trial of hemp seed oil tested a different product and says nothing about CBD. For any CBD hemp oil for arthritis, the certificate of analysis (COA) shows the CBD content.

What does research show about CBD for arthritis?

Is CBD good for arthritis? The evidence is mixed and low-certainty. The clearest benefit so far came from CBD on the skin: a thumb-arthritis cream met its main goal in a placebo-controlled trial (see the CBD cream section below). Reviews that pooled chronic-pain trials were less positive: a 2026 Annals of Internal Medicine review of 25 chronic-pain trials (2,303 people, 64% with nerve pain) found low-THC, CBD-dominant products may not improve pain, and oral CBD alone did no better than placebo in 4 trials with 334 people (AHRQ 2025, moderate strength of evidence).

For oral CBD, one placebo-controlled pilot gave a favorable signal: in 36 people having both knees replaced, a post hoc test found lower opioid use with 400 mg than with placebo, while the planned comparison found no significant difference. The abstract reports, without test results, that the 400 mg group also had lower pain scores and needed less rescue pain medicine but used more NSAIDs, and that the CBD groups reported better self-rated sleep but had higher levels of IL-6, a marker of inflammation. The 800 mg group showed no opioid-sparing effect (Sideris 2026). A 2026 osteoarthritis (OA) meta-analysis of 4 pooled trials found no significant benefit, and no placebo-controlled trial of oral CBD in our review met its main goal.

Further reviews, among them a meta-analysis and a clinical guideline, reported a benefit or a favorable signal; the table below lists 6 of them as of November 13, 2026, and it is a selection, not a full list. The less positive reviews are cited in the two paragraphs above, among them the 2026 chronic-pain review of 25 trials (low-THC, CBD-dominant products may not improve pain) and the 2026 osteoarthritis meta-analysis of 4 trials (no significant benefit).

Reviews and one guideline that reported a benefit or a favorable signal: a selection, as of November 13, 2026
Review What it covered What it reported Its own limit
de Carvalho 2024 Systematic review of 28 articles on cannabis in rheumatological diseases: 13 on fibromyalgia and 15 on other conditions (5 randomized double-blind studies, 5 surveys, 3 case reports, 1 prospective open study and 1 cross-sectional study; no participant total given). Products were of several kinds, among them medical cannabis, cannabis oil, CBD and a CBD + THC spray, so this is not a CBD-only result. For better osteoarthritis pain or function, its full text cites a case report, two patient surveys (one is the Frane 2022 survey of 428 people) and a study of opioid prescriptions. Its arthritis studies also include the Blake 2006 spray trial and the Vela 2022 oral CBD trial, which found no difference from placebo; all three are already cited on this page. Cannabis showed a good pain-relieving effect in osteoarthritis (3 studies); 2 rheumatoid arthritis papers showed a decrease in pain, and 1 of them a reduction in measures of inflammation. The authors call cannabis “an interesting option” for rheumatological diseases. Small studies with short observation periods; no comparison with standard treatments; the authors say cannabis should be explored in more studies.
Xiao 2024 Scoping review of 10 studies of cannabis-based medicines in osteoarthritis: 4 randomized trials, 3 cross-sectional surveys, 2 case studies and 1 cohort study (no participant total given). The abstract does not say which products the studies tested (CBD alone or with THC), so this is a result for cannabis-based medicines, not a CBD-only result. 6 of the 10 studies (60%) reported statistically significant improvements in pain, and several found the medicines were associated with less opioid use. The studies with larger samples and longer exposure did not find significant benefits for pain. Mixed evidence; the authors call the data insufficient to make recommendations.
Dubois 2024 Systematic review of 7 studies of medical cannabis in adults with osteoarthritis, published 2012 to 2022: 2 randomized trials and 5 observational (non-randomized) studies (no participant total given). The abstract does not break the products down by CBD or THC content, so this is a medical cannabis result, not a CBD-only result. All 5 observational studies reported lower pain, less opioid use and/or better osteoarthritis function, and 1 of the 2 randomized trials reported improved pain. The authors write that the consensus across the 7 studies was that medical cannabis was effective for a subgroup of people with osteoarthritis pain. Low-quality evidence: high risk of bias and low study quality.
Bell 2024 Clinical practice guideline built on a systematic review of cannabinoid-based medicines for chronic pain (THC, CBD and combined products together, not CBD alone): 70 articles, 19 of them systematic reviews and 51 original studies. Its arthritis recommendation rests on 3 sources, among them the Blake 2006 spray trial and the Hunter 2018 gel abstract, both already in the trial table below. The guideline recommends cannabinoid-based medicines as an add-on for managing chronic pain in people with arthritic conditions who are not getting an adequate response from other approaches (strong recommendation, low-quality evidence), and says research typically shows moderate benefit of these medicines in chronic pain. Low-quality evidence for the arthritis recommendation; the guideline says the strongest chronic-pain evidence is for THC formulations, not CBD. It was funded by the Canadian Institutes for Health Research, the Arthritis Society of Canada and Canopy Growth Corporation, a cannabis company; the guideline states that neither the funders nor the authors’ institutions played any role in developing it.
Guillouard 2021 Systematic review and meta-analysis of cannabis use by people with rheumatologic diseases: 10,873 patients, 2,900 of whom reported using cannabis. It covers cannabis as patients used it across rheumatologic diseases (fibromyalgia and lupus included), so this is not a result for CBD or for arthritis alone. Cannabis use was associated with a decrease in pain intensity: scores on a visual analogue pain scale were 8.2 at baseline vs 5.6 over time (pooled effect size -1.75, 95% confidence interval -2.75 to -0.76; the abstract gives the unit as mm but no scale range). Cannabis users also had higher pain intensity than non-users (5.0 vs 4.1, a statistically significant difference). None stated in the abstract. The pain result is an association over time among cannabis users, pooled across different rheumatologic diseases; the abstract does not say how many studies or people were pooled for it.
Fitzcharles 2016 Systematic review of 4 short-term randomized trials of plant-derived or synthetic cannabinoids, not CBD alone, in 203 patients with rheumatoid arthritis, fibromyalgia or osteoarthritis. The abstract does not name the trials. Cannabinoids had a statistically significant effect on pain in 2 trials and on sleep in 2, and quality of life improved in 1; the authors write that pain relief and the effect on sleep “may have some potential therapeutic benefit, but with considerable mild to moderate adverse events”. The osteoarthritis trial was stopped early for futility. Extremely small samples, short studies and high risk of bias in all 3 completed studies; the authors found insufficient evidence to recommend cannabinoids for rheumatic diseases.

The 2006 CBD + THC spray trial reported a small drop in a rheumatoid arthritis disease-activity score over 5 weeks (Blake 2006); no trial in our review found that CBD on its own changes the course of arthritis. The 2022 Danish hand trial is sometimes described as topical, but it used oral tablets (Vela 2022).

How the evidence has changed: the earliest studies were mostly encouraging. Animal studies in 2000 and 2016, a 2006 rheumatoid arthritis spray that also contained THC, and a secondary analysis of a 2018 knee-gel trial that missed its main measure all pointed to benefit. From 2022 to 2025, placebo-controlled trials tested CBD without THC in people: a thumb cream met its main goal, while three oral arthritis trials of 8 to 12 weeks, the newest of them Mojoli 2025, and a topical used after knee replacement found no difference from placebo. In October 2026 the HSS knee-replacement pilot was published: a post hoc test favored 400 mg, while the planned test found no significant difference (Sideris 2026); it gave four doses around surgery, not daily CBD for weeks. The other 2026 results (Kruger, Zylla and the McMaster pilot) come from a registry posting or from studies without a placebo group.

What lab and animal studies suggest

In animal studies, CBD slowed collagen-induced arthritis in mice (Malfait 2000) and lowered joint swelling and pain behavior in rats (Hammell 2016). This animal work is one reason CBD oil for inflammatory pain is being tested in people; see CBD for inflammation and the endocannabinoid system.

What CBD users report in surveys

Joint pain was the third most common medical reason US adults gave for using CBD (11.2%), and 83% of 428 people with arthritis who chose CBD said their pain improved. In the Arthritis Foundation’s 2019 survey of more than 2,600 people with arthritis (a patient-organization survey of what users reported, with no comparison group), 29% said they currently used CBD for their arthritis symptoms, and the Foundation reports that most current users reported relief of pain (no percentage given). Of those currently using CBD for arthritis symptoms, roughly 3 out of 4 said it was effective or very effective for several symptoms; 67% reported better physical function, 71% better sleep and over 30% relief from morning stiffness. These reports reflect the products, amounts and lengths of use people chose for themselves. Studies of prescription cannabis medicines containing THC, CBD or both also reported lower pain scores, with no comparison group. In an Australian clinic study, pain intensity scores fell among 199 people with arthritis, including those on CBD-only products (p = 0.018); 51% of the study’s whole chronic-pain group reported a side effect (Schubert 2023). In a UK registry, 77 people with osteoarthritis reported lower pain scores at every follow-up to 12 months, and 22.08% recorded side effects (Francis 2024). Surveys and studies without a comparison group cannot show how much of an improvement came from the product itself rather than expectation, time or other treatments, which is what a placebo group measures. In the 86-person knee trial, pain improved in both groups: WOMAC pain scores (a standard knee-arthritis pain questionnaire) fell 2.5 points on CBD and 2.4 on placebo.

Human trials of CBD for arthritis, in one table (as of November 13, 2026)

Of 7 placebo-controlled trials of CBD without THC for arthritis or knee replacement with results in a journal or conference abstract (721 people), 1 met its main goal: the 18-person thumb-cream trial. The other 6 (703 people) found no difference from placebo on their main measure, though a secondary analysis of the 320-person knee-gel trial and a post hoc test in the 36-person knee-replacement pilot each favored the lower of two doses. The table lists trials oldest first; our full trial list adds 3 more.

Human trials of CBD in arthritis and joint surgery, as of November 13, 2026
Study Design People and condition CBD form and daily amount Length Main result Study quality (our rating)
Blake 2006 Randomized 58, rheumatoid arthritis CBD + THC spray (nabiximols) 5 weeks Small pain and sleep gains; not in the tally Low
Hunter 2018 Randomized, abstract only 320, knee OA Skin gel, 250 or 500 mg 12 weeks Main measure: no difference; a secondary analysis favored 250 mg Low
Vela 2022 Randomized 136, hand OA or psoriatic arthritis Oral tablets, 20-30 mg 12 weeks No difference Moderate
Haffar 2022 Randomized 80, after knee replacement Topical, 3 times daily 2 weeks No difference Low
Heineman 2022 Crossover 18, thumb arthritis Cream, 1 mL twice daily 2 weeks per arm Pain and function scores improved vs shea butter Low
Pramhas 2023 Randomized 86, knee OA Oral, 600 mg 8 weeks No difference; more liver-enzyme rises, 15 vs 5 Moderate
Mojoli 2025 Randomized 45, knee OA Oral oil, 45 mg 60 days No difference Low
Sideris 2026 (HSS pilot) Randomized pilot 36, both knees replaced Epidiolex oral solution, 4 doses of 400 or 800 mg around knee-replacement surgery (perioperative) Around surgery; opioid use counted over 72 hours Main measure: no difference; a post hoc test favored 400 mg Low

Evidence by arthritis type and joint

Placebo-controlled trials with results in a journal or conference abstract
Type Trials What they found
Knee OA 3, plus 2 around knee replacement surgery None met its main goal
Hand or thumb OA 2 Cream met its goal; oral did not
Hip 0 One recruiting
Shoulder, feet, ankles, wrists, neck 0 One shoulder trial recruiting
Psoriatic arthritis 1 No difference
Rheumatoid arthritis 0 without THC One CBD + THC spray trial: small pain and sleep gains

Does CBD help with knee osteoarthritis?

Two knee trials found a possible benefit: a secondary analysis of a 320-person gel trial favored its lower dose, and a post hoc test in a 36-person knee-replacement pilot found lower opioid use with 400 mg of oral CBD than with placebo. On their main measures, all five placebo-controlled knee trials with results in a journal or conference abstract (three in knee OA, two around knee replacement) found no difference (Pramhas 2023, Mojoli 2025, Hunter 2018, Haffar 2022, Sideris 2026), so the trials so far do not show a clear benefit of CBD for knee osteoarthritis. A topical knee trial was registered May 29, 2026 (NCT07638189).

Does CBD help with arthritis in the hands or thumb?

Mixed. For CBD for arthritis in hands, the 18-person thumb-cream trial met its goal, while the 136-person oral trial did not. In a small open-label gel study, people reported gains while using the gel, and the gains faded after they stopped; the study had no comparison group.

What about hips, shoulders, feet and other joints?

A recruiting trial compares CBD, THC and placebo in about 100 adults with hip or knee OA (NCT06878417). On CBD for hip pain, 24% of 200 people with hip or knee osteoarthritis had tried CBD, and those who used it reported worse joint scores than those who did not (Deckey 2021); this one-time survey cannot show whether CBD affected their joints or whether people with worse symptoms were more likely to try it. In a 2022 survey of 823 orthopaedic sports-medicine patients (shoulder, knee, hip, ankle and elbow problems, not only arthritis), 19% had used CBD for their joint problem, and 75% of users (104 of 138) used a topical form; users reported higher pain than non-users (6.1 vs 5.6 on a 0 to 10 scale; Deckey 2022). Around hip or knee replacement, 16.4% of 195 patients used CBD or THC products, with no significant difference from non-users in opioid use or pain scores (Runner 2020). Neither study was randomized, so neither can show cause.

For CBD for arthritis in feet, ankles, wrists or the neck we found no trial; a shoulder-surgery trial is recruiting (NCT06381791). Our CBD for pain article covers back pain.

What about rheumatoid and psoriatic arthritis?

For rheumatoid arthritis, the only placebo-controlled trial used a CBD and THC spray and reported small pain and sleep gains over 5 weeks (Blake 2006; Zintziovas 2026), and in a 2026 study without a placebo group that included rheumatoid arthritis, people reported improvement on all 3 cannabinoid capsules tested, one of which contained THC and one no CBD (Kruger 2026). In a UK registry of 192 people with inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis) who had taken prescribed cannabis medicines for at least 24 months, average pain severity fell from 5.95 to 3.98 on a 0 to 10 scale and 14.06% reported side effects (Sajeev 2026). That study had no comparison group, and by 24 months the medicines were mostly THC (a median of 20.54 mg CBD and 145.63 mg THC a day), so it is not a result for CBD alone. On CBD for psoriatic arthritis, the 136-person trial, which included people with psoriatic arthritis or hand osteoarthritis, found no difference from placebo. Both conditions need disease-modifying treatment from a doctor (Arthritis Foundation).

Does CBD cream work for arthritis? What topical studies found

Trials of topical CBD oil for arthritis disagree, but they include the clearest positive result: an 18-person thumb-cream trial met its goal, and a 320-person knee gel trial favored the lower of its two doses in a secondary analysis, though neither that trial nor an 80-person trial after knee replacement met its main goal. A 2026 scoping review called topicals the most encouraging form, though not yet ready for routine clinical use.

Some CBD reaches the body: low levels were found in every urine sample after 4 weeks of a gel (Bawa 2024). The Arthritis Foundation says it is not clear topical CBD gets below the skin. Many topical products also contain menthol, capsaicin or camphor, so the Arthritis Foundation says it can be hard to tell whether an effect comes from the CBD or another ingredient.

Topical CBD products sold for joints include creams, lotions, balms, salves, ointments, roll-ons and massage oils; the published arthritis trials tested only creams, gels and a topical applied around the knee after knee replacement (quality checks).

CBD for Arthritis by the Numbers (October 2026)

Metric Value As of Source
Registered studies 32 (19 on arthritis itself, 13 of those on the knee) 2026-10-23 ClinicalTrials.gov
Completed 12 of 32 2026-10-23 ClinicalTrials.gov
Posted results 4 of 12 completed; paper found for 8 2026-10-23; papers 2026-11-13 ClinicalTrials.gov
People enrolled 757 in 17 studies; 1,436 planned in 15 2026-10-23 ClinicalTrials.gov
Completed Phase 3 trials, CBD without any THC 0 2026-10-23 ClinicalTrials.gov
New registrations, 2025-2026 4 2026-10-23 ClinicalTrials.gov
PubMed papers 169; 98 in 2020-2024 vs 16 in 2015-2019 2026-10-23 PubMed
Tagged randomized trials 6 of 169 2026-10-23 PubMed
US searches for “cbd for arthritis” Peak an estimated 3,770 a month (August 2021); last 12 complete months averaged 1,258, 48.6% below 2019 2026-10-23 Ahrefs, US

The number of registered studies shows research interest; the trial tables above show the results.

Cannabidiol Life compiled these figures by hand from ClinicalTrials.gov and PubMed on October 23, 2026; the count of completed studies with a results paper was updated on November 13, 2026.

Cite this data: Cannabidiol Life, “CBD for Arthritis by the numbers (October 2026),” cbdoilsandedibles.com, https://cbdoilsandedibles.com/health/cbd-for-arthritis/, data as of 2026-10-23; results-paper count updated 2026-11-13.

How much CBD, and which forms, did arthritis studies use?

There is no official dose of CBD for arthritis, and research has not shown what amount works for a given person. In studies, adults received 20 to 600 mg a day by mouth for 8 to 12 weeks (Vela 2022; Mojoli 2025; Pramhas 2023), and a skin-gel trial used 250 or 500 mg a day (Hunter 2018). A knee-surgery pilot gave four doses of 400 or 800 mg of Epidiolex, a prescription CBD solution, around surgery (NCT04749628): a post hoc test found lower opioid use in the 400 mg group than on placebo, and the planned test found no significant difference at either dose (Sideris 2026). These are the amounts researchers used in studies. They are not dosing advice.

Onset: Arthritis Foundation guidance, not trial data
Form Onset In arthritis trials?
Oil under the tongue 15-45 minutes No (only a CBD + THC mouth spray, in rheumatoid arthritis)
Capsule or swallowed oil 1-3 hours Yes
CBD gummies for arthritis, or other edibles 1-3 hours No
Cream or gel Not stated Yes
Vape Not stated No

Arthritis Foundation experts discourage edibles, and say inhaling vapor oils and their chemical byproducts carries risks, especially for people with inflammatory arthritis, so vaping is typically not recommended. 39% of CBD gummies tested contained delta-9 THC. No trial compared forms, so research has not shown which is the best way to use CBD for pain.

Where does CBD fit with standard arthritis care?

The 2019 American College of Rheumatology and Arthritis Foundation osteoarthritis guideline makes no recommendation on CBD; it names medical marijuana only as a topic needing more research. Its strongly recommended options, such as exercise, weight loss and NSAIDs by mouth, are listed in the FAQ.

We found no head-to-head trial against an arthritis medicine. Added to paracetamol (acetaminophen), CBD and placebo gave the same pain scores (Pramhas 2023). Do not stop, reduce or change any prescribed medicine or treatment without talking to the doctor who prescribed it.

In a 2025 test of 18 US CBD tinctures, price did not predict label accuracy.

Questions to ask your doctor before you try CBD

  • What goal will we track in a symptom diary?
  • Can we follow up about every 3 months, as the Arthritis Foundation advises?
  • When do we stop? Do I need liver tests?

Is CBD safe? Side effects, liver effects and drug interactions

Outside childhood epilepsy, diarrhea was the side effect most clearly linked to CBD in a review of 12 trials with 803 people. Talk to your doctor before using CBD, especially if you take any medicines or supplements, have liver problems, or have a health condition.

Side effects reported in studies

At prescription seizure-treatment doses of 10 to 20 mg per kg a day, sleepiness or sedation affected 32% vs 11% on placebo in Epidiolex seizure trials (label). The FDA lists decreased appetite and irritability; consumers report dry mouth. A 2026 review found that products with as much THC as CBD, or more, raised dizziness, sedation and nausea, while CBD alone may not have increased harms in those short trials. In a 36-person knee-replacement pilot of Epidiolex, the 800 mg group had more side effects, and anxiety and depression scores were higher in the CBD groups, particularly at 800 mg; the abstract gives no test results for these differences, and the trial’s registry results show the anxiety and depression scores were already higher in the CBD groups before surgery (Sideris 2026).

The FDA says animal studies showed male reproductive toxicity from CBD, and the NIH lists male reproductive harm among CBD’s risks, with liver injury and drug interactions (NCCIH).

Liver effects

Liver enzymes passed 3 times the upper limit of normal in 5.6% of healthy adults taking 5 mg per kg a day for 4 weeks, vs 0% on placebo; the authors called for research on the lower doses consumers commonly use. In an 8-week knee trial of 600 mg a day, liver enzymes rose in 15 people on CBD vs 5 on placebo (Pramhas 2023). In Epidiolex seizure trials, the rate above 3 times normal was 13% vs 1% at prescription doses of 10 to 20 mg per kg a day, and 3% in patients taking neither valproate nor clobazam, two seizure medicines (label).

Drug interactions

CBD can affect how other medicines work, which can cause serious side effects. Using CBD with alcohol or with medicines that cause drowsiness, such as some medicines for anxiety, panic, stress or sleep, raises the risk of sleepiness and injury. Ask your doctor or pharmacist before combining CBD with any medicine or supplement.

  • CYP3A4, CYP2C19 and CYP2C9 enzymes process CBD (Nachnani 2024).
  • Warfarin’s effect (INR) rose in 6 of 7 case reports (Smythe 2023).
  • In 12 healthy volunteers, one 30 mg dose of CBD raised blood levels of the antidepressant amitriptyline by 13% (a ratio of 1.13) and did not significantly change tramadol levels; the authors say interactions may be more pronounced with daily use (Gorbenko 2026).
  • A 2026 review catalogued 1,289 possible drug interactions with CBD and rated 19 as major (among them colchicine, leflunomide, buprenorphine and morphine) and 828 as of unknown significance; the authors conclude that only a small group warrants consideration in clinical practice (Keller 2026).
  • Possible interactions (Arthritis Foundation): NSAIDs, acetaminophen, corticosteroids, tofacitinib, tramadol, some antidepressants, gabapentin, pregabalin.

Who should avoid CBD

Do not use CBD if you are pregnant, planning a pregnancy or breastfeeding. The FDA strongly advises against using CBD, THC or marijuana in any form during pregnancy or while breastfeeding.

CBD products are not for children. Keep them out of reach of children and pets. If a child swallows a CBD or THC product, call Poison Control at 1-800-222-1222 or get medical care right away.

When to see a doctor

Get emergency care (call 911) for sudden, severe or unexplained pain, chest pain, trouble breathing, or signs of a stroke. See your doctor for new, worsening or lasting joint symptoms.

How to check a CBD product’s quality

How to check a CBD product’s quality: read its certificate of analysis (COA) from an accredited third-party lab. See our guides to reading a COA and verifying the lab.

  • A recent batch COA using validated test methods (Arthritis Foundation)
  • Total THC per container (0.4 mg limit from December 11, 2026)
  • CBD per serving matching the label
  • Contaminant tests
  • No disease claims (the FDA sends warning letters)

How often are CBD labels wrong?

Labels are not always accurate: a 2024 study that tested 202 US CBD products found that 74% were off their labeled CBD amount by 10% or more (Gidal 2024). A 2022 test found THC in 35% of hemp skin products (Spindle 2022).

Products, year Accurately labeled THC found
Oils, tinctures and vape liquids sold online, 2017 31% 21%
Creams and balms, 2022 24% 35%
202 US products, 2024 74% missed their labeled CBD by 10% or more Not stated
Gummies, 2025 70% missed by over 10% 39%

What contaminants have labs found in CBD products?

In the 2024 test (funded by Epidiolex maker Jazz Pharmaceuticals), labs detected heavy metals in 44 of 202 products, residual solvents in 181 and pesticides in 30; only 1% to 3% of detections exceeded a regulatory limit. The FDA says CBD products may be contaminated with THC, pesticides, heavy metals, bacteria or fungus.

A 2026 study of oils sold in Europe, not the US, found PAHs, a group of chemical contaminants, in all 186 CBD and related cannabinoid oils it tested, and 54% were above EU limits (Binova 2026).

Is CBD legal? Federal law is changing. Under the 2018 Farm Bill definition, hemp (including hemp-derived CBD) is cannabis with no more than 0.3% delta-9 THC by dry weight, and it is not a controlled substance. A new federal definition applies in two steps (section 781 of Public Law 119-37, with start dates set by Public Law 119-103). Starting November 12, 2026, hemp products that contain cannabinoids the plant cannot produce naturally no longer count as hemp. Starting December 11, 2026, the rest of the definition applies. It counts total THC, including THCA, and a finished hemp product such as a CBD oil or gummy qualifies as hemp only if each container holds no more than 0.4 mg of total THC and similar cannabinoids, and contains no cannabinoids that were synthesized or manufactured outside the plant. Some full-spectrum CBD products contain more THC than that. State laws differ and can be stricter. This is general information, not legal advice.

Frequently asked questions

Does CBD really work for arthritis pain?

Results are mixed. In placebo-controlled trials, a thumb-arthritis cream improved pain and function, a knee gel favored its lower dose in a secondary analysis, a post hoc test in a knee-replacement pilot found lower opioid use with 400 mg of oral CBD, and a CBD + THC spray brought small pain and sleep gains in rheumatoid arthritis. Apart from the cream, the trials of CBD without THC, including all 4 oral trials, found no difference from placebo on their main measure.

What are the potential side effects of using CBD oil?

A 2026 review found CBD alone may not have increased harms in short trials. Diarrhea was the side effect most clearly linked to CBD outside childhood epilepsy. In Epidiolex seizure trials at prescription doses of 10 to 20 mg per kg a day, sleepiness or sedation affected 32% vs 11% on placebo (label). At a daily dose the authors said is higher than consumers commonly use, liver enzymes passed 3 times normal limits in 5.6% of healthy adults vs 0% on placebo. CBD can interact with warfarin.

Is there an official CBD dose for arthritis?

No. There is no official dose of CBD for arthritis. Trials tested different daily amounts of oral CBD (Vela 2022; Mojoli 2025; Pramhas 2023), an oral CBD solution around knee surgery (NCT04749628; Sideris 2026) and a skin gel at two strengths (Hunter 2018). The dose section above lists the amounts each trial used.

Has any study compared CBD creams with CBD oils for arthritis?

No arthritis trial had compared forms head to head as of November 13, 2026. An 18-person cream trial met its goal; topical trials of 80 and 320 people and oral trials of 36, 45, 86 and 136 people did not. Gummies and vapes have not been tested in arthritis trials.

What is the best treatment for arthritis pain?

The 2019 ACR/Arthritis Foundation osteoarthritis guideline strongly recommends exercise, weight loss for knee or hip osteoarthritis with overweight, self-management programs, tai chi for knee or hip osteoarthritis, a cane, a knee brace or a thumb-base hand orthosis, NSAIDs by mouth, NSAID gels for the knee, and steroid injections into the knee or hip. It makes no recommendation on CBD.

How we researched this

We do not sell or recommend products on this page. Every study cited was checked at PubMed or the publisher, or on an archived copy of the publisher’s page. Figures from Cannabidiol Life’s Evidence Tracker show the date and source used. Trial-table quality ratings are our own, by design, size and publication type. On November 13, 2026 we searched Cannabidiol Life’s research library (5,059 PubMed records) and found 150 papers on CBD or medical cannabis and arthritis that were not yet in our review, and a wider search of the library’s pain and joint papers found more. We checked 52 of these papers at PubMed and added the 8 studies that met this page’s rules. On the same day we also added 7 more sources from our October research, a selection and not a full list, each of which reported a favorable result: 5 reviews and 1 clinical guideline, checked at PubMed, and 1 patient survey, read on an archived copy of the Arthritis Foundation’s page.

Every human trial in our review

Every human randomized or controlled trial in our evidence review, as of November 13, 2026
Study and year People Product and route Arthritis type Main result
Vela 2022 136 CBD tablets, by mouth Hand OA or psoriatic arthritis No difference from placebo
Pramhas 2023 86 CBD by mouth, added to paracetamol Knee OA No difference from placebo; liver-enzyme rises in 15 vs 5
Mojoli 2025 45 CBD-rich oil, by mouth Knee OA No difference from placebo
Hunter 2018 (conference abstract) 320 CBD gel on the skin Knee OA Main measure no different from placebo
Haffar 2022 80 CBD on the skin around the knee After knee replacement No drop in pain, sleep problems or opioid use vs placebo
Heineman 2022 18 CBD cream on the thumb (crossover) Thumb arthritis Pain and function improved vs shea butter
Sideris 2026 (HSS pilot) 36 Epidiolex oral solution, by mouth, 4 doses around surgery Knee replacement (both knees) No significant difference from placebo in opioid use over 72 hours, in morphine milligram equivalents (400 mg: 144 vs 209, p=0.10; 800 mg: 203.2 vs 209, p=0.98); a post hoc test favored 400 mg (p=0.04)
Blake 2006 58 CBD + THC mouth spray (nabiximols) Rheumatoid arthritis Small pain and sleep gains vs placebo
McMaster pilot (registry results, 2026) 39 CBD oil with a little THC (25 to 1), by mouth, around surgery Knee replacement Pain at 6 months 3.5 on the oil vs 2.6 on placebo (placebo lower); built to test feasibility, not benefit
Kruger 2026 164 3 cannabinoid capsules by mouth (one with THC, one with no CBD); no placebo OA, rheumatoid arthritis or fibromyalgia Self-reported improvements on all 3 capsules; no placebo group
Zylla 2026 21 CBD balm vs THC balm on the hands, open-label; no placebo Hand joint pain from breast-cancer drugs (not arthritis) Large improvement in 18% on the CBD balm vs 50% on the THC balm; not designed to compare them

Not listed: studies with no comparison group (such as a small open-label gel study, Bawa 2024), a hemp seed oil trial that tested no CBD, and safety trials in healthy adults. The first 7 rows are the trials counted in the tally above the trial table.

Important safety and legal information

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have about a medical condition.

These statements have not been evaluated by the Food and Drug Administration. Hemp-derived CBD products are not intended to diagnose, treat, cure, or prevent any disease.

For side effects, liver effects, drug interactions and who should avoid CBD, including during pregnancy and breastfeeding, see the safety section above.

Sources

  1. Chou R, Fu R, Ahmed AY, Morasco BJ. Cannabis-Based Products for Chronic Pain: An Updated Systematic Review. Ann Intern Med. 2026;179(2):230-241. PubMed 41429020
  2. Chou R, Ahmed AY, Dana T, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update (Comparative Effectiveness Review No. 250). Agency for Healthcare Research and Quality; 2025. PubMed 40956916
  3. Abafita BJ, Singh A, Aitken D, Antony B. Efficacy and Safety of Cannabis Extracts for the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis of Preclinical and Human Studies. Pain Res Manag. 2026;2026(1):e3998239. PubMed 42515994
  4. Tee JY, Thahir A, Krkovic M. The role of cannabis-based medicinal products (CBMPs) in managing osteoarthritis symptoms: a scoping review of current evidence and future directions. Clin Rheumatol. 2026;45(5):2483-2496. PubMed 41870683
  5. Zintziovas N, Karakosta A, Voulgari P, et al. Cannabinoids for pain management in rheumatoid arthritis: a scoping review of clinical evidence and mechanisms. Rheumatol Int. 2026;46(10):275. PubMed 42831900
  6. Mojoli A, Haider O, Fakih Y, et al. Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial – CANOA – cannabis for osteoarthritis. Front Pharmacol. 2025;16:1657065. PubMed 41487518
  7. Pramhas S, Thalhammer T, Terner S, et al. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Lancet Reg Health Eur. 2023;35:100777. PubMed 38033459
  8. Vela J, Dreyer L, Petersen KK, et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206-1214. PubMed 34510141
  9. Heineman JT, Forster GL, Stephens KL, et al. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. J Hand Surg Am. 2022;47(7):611-620. PubMed 35637038
  10. Haffar A, Khan IA, Abdelaal MS, et al. Topical Cannabidiol (CBD) After Total Knee Arthroplasty Does Not Decrease Pain or Opioid Use: A Prospective Randomized Double-Blinded Placebo-Controlled Trial. J Arthroplasty. 2022;37(9):1763-1770. PubMed 35390457
  11. Hunter DJ, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. Osteoarthritis Cartilage. 2018;26(Suppl 1):S26 (OARSI World Congress abstract). DOI 10.1016/j.joca.2018.02.067
  12. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50-2. PubMed 16282192
  13. Hospital for Special Surgery. Effects of Cannabidiol (CBD) Oral Solution in Patients Undergoing Bilateral Total Knee Arthroplasty (NCT04749628), results first posted 2026-05-26. ClinicalTrials.gov
  14. Bawa Z, Lewis D, Gavin PD, et al. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Sci Rep. 2024;14(1):11792. PubMed 38783008
  15. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561-6. PubMed 10920191
  16. Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936-48. PubMed 26517407
  17. Abbasifard M, Moosavi Z, Azimi M, et al. Effect of Topical Hemp (Cannabis sativa L.) Seed Oil on Knee Osteoarthritis: A Randomized Double-Blind Controlled Trial. Pain Manag Nurs. 2025;26(1):e74-e81. PubMed 39256070
  18. Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025;185(9):1070-1078. PubMed 40622698
  19. Jazz Pharmaceuticals. EPIDIOLEX (cannabidiol) oral solution: Full Prescribing Information (revised 5/2026; Medication Guide revised 7/2025). DailyMed, US National Library of Medicine, SPL version 35, published June 15, 2026. DailyMed
  20. Nachnani R, Knehans A, Neighbors JD, et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. PubMed 38868665
  21. Smythe MA, Wu W, Garwood CL. Anticoagulant drug-drug interactions with cannabinoids: A systematic review. Pharmacotherapy. 2023;43(12):1327-1338. PubMed 37740600
  22. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020;45(11):1799-1806. PubMed 32268347
  23. Binova Z, Maly M, Drabova L, et al. Poorly labeled CBD and related cannabinoid oils marketed in Europe: a hidden risk for consumers? Insights from a long-term study. Anal Bioanal Chem. 2026. PubMed 42611266
  24. Johnson ED, Kilgore MW, Stafford M, et al. Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. Cannabis Cannabinoid Res. 2025;10(6):710-718. PubMed 40454463
  25. Sullivan Z, Lapierre C, Weiser Erlandson L, Pham L. Substances of Health Concern: Label Accuracy of Cannabidiol and Tetrahydrocannabinol in Commercial Cannabidiol Tinctures from the United States. Cannabis Cannabinoid Res. 2025. PubMed 40518984
  26. Gidal BE, Vandrey R, Wallin C, et al. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front Pharmacol. 2024;15:1335441. PubMed 38562466
  27. Spindle TR, Sholler DJ, Cone EJ, et al. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores. JAMA Netw Open. 2022;5(7):e2223019. PubMed 35857320
  28. Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708-1709. PubMed 29114823
  29. US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). fda.gov
  30. US Food and Drug Administration. What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD. fda.gov
  31. National Center for Complementary and Integrative Health. Cannabis (Marijuana) and Cannabinoids: What You Need To Know. nccih.nih.gov
  32. US Food and Drug Administration. What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding. fda.gov
  33. Arthritis Foundation. CBD for Arthritis Pain: What You Should Know (updated July 29, 2024). arthritis.org
  34. Arthritis Foundation. Arthritis Foundation CBD Guidance for Adults with Arthritis (2019). arthritis.org
  35. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-162. PubMed 31908149
  36. Frane N, Stapleton E, Iturriaga C, et al. Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study. J Cannabis Res. 2022;4(1):47. PubMed 35999581
  37. Deckey DG, Lara NJ, Gulbrandsen MT, et al. Prevalence of Cannabinoid Use in Patients With Hip and Knee Osteoarthritis. J Am Acad Orthop Surg Glob Res Rev. 2021;5(2). PubMed 33986220
  38. Satybaldiyeva N, Yang KH, Kepner W, Ferran K, Leas EC. Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults. J Cannabis Res. 2025;7(1):100. PubMed 41366718
  39. Weissgerber A, Hermanns-Clausen M, Lamy E. Over the counter CBD products in Germany: an exploratory survey about consumption patterns and health related effects. Front Pharmacol. 2025;16:1571025. PubMed 40469987
  40. Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (IF13136, updated September 28, 2026). congress.gov. Laws: Public Law 119-37; Public Law 119-103
  41. Kruger DJ, Dautrich T, Hall B, et al. Assessing the Efficacy of Cannabinoid Compositions for Treating 3 Classes of Chronic Pain: A Real-World Evidence Study. Clin Ther. 2026;48(9):907-912. PubMed 42140793
  42. Zylla D, Idossa D, Borrero M, et al. A Randomized, Open-Label Trial to Assess Feasibility and Tolerability of Topical Cannabis Balms for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS). Cannabis Cannabinoid Res. 2026;11(1):30-35. PubMed 41467893
  43. McMaster University. The Effect of Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following Total Knee Arthroplasty: A Multicenter, Randomized Pilot Trial (NCT03825965), results first posted 2026-09-08. ClinicalTrials.gov
  44. Sideris A, Chan W, Liu J, et al. Effects of cannabidiol (CBD) oral solution in patients undergoing bilateral total knee arthroplasty: A randomized, controlled, parallel, triple blind, pilot study. J Pain. 2026;51:106477. PubMed 42913966
  45. Schubert EA, Johnstone MT, Benson MJ, Alffenaar JC, Wheate NJ. Medicinal cannabis for Australian patients with chronic refractory pain including arthritis. Br J Pain. 2023;17(2):206-217. PubMed 37057257
  46. Francis A, Erridge S, Holvey C, et al. Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry. J Pain Palliat Care Pharmacother. 2024;38(2):103-116. PubMed 38669060
  47. Deckey DG, Doan M, Hassebrock JD, et al. Prevalence of Cannabinoid (CBD) Use in Orthopaedic Sports Medicine Patients. Orthop J Sports Med. 2022;10(4):23259671221087629. PubMed 35400139
  48. Runner RP, Luu AN, Nassif NA, et al. Use of Tetrahydrocannabinol and Cannabidiol Products in the Perioperative Period Around Primary Unilateral Total Hip and Knee Arthroplasty. J Arthroplasty. 2020;35(6S):S138-S143. PubMed 32173619
  49. Sajeev A, Erridge S, Datta A, et al. UK Medical Cannabis Registry: An Updated Analysis of Inflammatory Arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2026;19:11795441261480709. PubMed 42724108
  50. Gorbenko AA, Post TE, Strugala PK, et al. Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study. Br J Clin Pharmacol. 2026;92(6):1595-1606. PubMed 41398552
  51. Keller GA, Aimar JA. The Pharmacokinetic and Pharmacodynamic Drug-drug Interaction Potential of Cannabidiol. Drug Metab Bioanal. 2026;19(2):107-118. PubMed 42841466
  52. de Carvalho JF, Ribeiro MFLDS, Skare T. Cannabis therapy in rheumatological diseases: A systematic review. North Clin Istanb. 2024;11(4):361-366. PubMed 39165706
  53. Xiao ATY, Turk T, Deol K, et al. Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review. Clin Rheumatol. 2024;43(8):2375-2390. PubMed 38853226
  54. Dubois C, Danielson EC, Beestrum M, Eurich DT. Medical cannabis and its efficacy/effectiveness on the management of osteoarthritis pain and function. Curr Med Res Opin. 2024;40(7):1195-1202. PubMed 38832841
  55. Bell AD, MacCallum C, Margolese S, et al. Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. Cannabis Cannabinoid Res. 2024;9(2):669-687. PubMed 36971587
  56. Guillouard M, Authier N, Pereira B, Soubrier M, Mathieu S. Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(2):549-556. PubMed 33159797
  57. Fitzcharles MA, Ste-Marie PA, Häuser W, et al. Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2016;68(5):681-8. PubMed 26548380
  58. Arthritis Foundation. Patients Tell Us About CBD Use (News Blog, August 8, 2019; survey of more than 2,600 people with arthritis). Internet Archive, archived page

Health hub · CBD for pain · CBD for inflammation · Endocannabinoid system · Reading a COA · Verifying a COA lab · CBD spectrum types

DON'T BE SHY

Leave a Reply

Your email address will not be published. Required fields are marked *

Pattern of white dots.
Cannabidiol Life white menu logo

IMPORTANT DISCLAIMER: